GlassScriptPhysician profile
Gregory T Winters
NPI 1932109998
$4,909.54
in general payments reported to CMS, 2019-2025
44 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $889 · 2020: $1,003 · 2021: $677 · 2022: $1,436 · 2023: $886 · 2024: $18.37.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $904.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $904.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,031.94 | 2019-2023 | Ozempic, Rybelsus |
| Abbvie INC. | $478.07 | 2020-2023 | Vraylar, Botox, Qulipta |
| Astrazeneca Pharmaceuticals LP | $331.86 | 2019-2023 | Farxiga, Breztri |
| Amgen INC. | $331.32 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $263.62 | 2020-2023 | Jardiance, Spiriva Respimat |
| Pfizer INC. | $251.00 | 2019-2023 | |
| Lilly USA, LLC | $204.60 | 2022-2023 | Mounjaro, Jardiance |
| Otsuka America Pharmaceutical, INC. | $155.62 | 2022-2023 | Rexulti |
| Merck Sharp & Dohme LLC | $126.35 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $108.74 | 2019-2022 | |
| Watermark Medical, INC. | $106.61 | 2022 | |
| Boston Scientific Corporation | $106.32 | 2019 | |
| Glaxosmithkline, LLC. | $105.65 | 2021-2023 | Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $101.86 | 2019-2023 | Xarelto |
| Biohaven Pharmaceutical Holding Company LTD. | $88.66 | 2022 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Winters listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.